enVVeno Medical Corporation’s board has approved a 1-for-35 reverse stock split, effective at 12:01 a.m. on Tuesday, January 20th. Shareholders will see their holdings consolidated after the market close on Monday, January 19th, with every 35 pre-split shares combining into one post-split share. This action is intended to increase the company’s per-share market value and maintain compliance with NASDAQ listing requirements.

On the first trading day since the split announcement, shares of enVVeno Medical traded down by 13.2%. Over the past year, the stock has ranged between a low near its sub-dollar threshold and a high reflecting its brief rally during clinical data releases. The company carries a market capitalization of approximately $6.34 million, a trailing twelve-month P/E ratio of –0.29 and a beta of 1.04, indicating above-average volatility relative to the broader market.

Wall Street sentiment remains cautious: Weiss Ratings reaffirmed a “sell (e+)” recommendation on December 29th, contributing to an average consensus of “reduce” from two covering analysts (one hold, one sell). Institutional investors hold 34.71% of the float. Notable recent stakes include Jane Street Group’s inaugural $51,000 position, Creative Planning’s $54,000 entry, CM Management’s $544,000 purchase, and Universal Beteiligungs’s $798,000 commitment. Geode Capital Management, which owns 199,509 shares valued at approximately $796,000, modestly increased its position by 2,211 shares in Q2.

enVVeno Medical is a clinical-stage device company developing subcutaneous vascular access systems under its Freedom® platform. Its lead candidate, the Freedom PICC System, features a low-profile implantable port linked to a flexible peripheral catheter, designed to reduce infection risk, device dislodgement and patient discomfort compared to traditional peripherally inserted central catheters (PICCs) and external tunneled lines. The company is preparing for pivotal studies and regulatory submissions to support commercialization.